<?xml version="1.0" encoding="UTF-8"?>
<fig id="fig6" orientation="portrait" position="float">
 <label>Figure 6.</label>
 <caption>
  <title>Llama-human chimeric antibodies protect mice from lethal RVFV infection.</title>
  <p>(
   <bold>A</bold>) Illustration of the VHH and hIgG
   <sub>1</sub>Fc-based llama-human chimeric antibodies. (
   <bold>B</bold>) SDS-PAGE of the purified chimeric antibodies under non-reducing and reducing conditions. (
   <bold>C</bold>) Neutralizing activity of the purified chimeric antibodies expressed as ND
   <sub>50</sub>. (
   <bold>D</bold>) Indirect RVFV-Gn
   <sub>ecto</sub>-based ELISA of the chimeric antibodies. (
   <bold>E</bold>) Illustration of the mouse experiment setup. (
   <bold>F</bold>) Survival curve of RVFV-infected mice treated with 200 µg 150-hIgG
   <sub>1</sub>Fc-104. (
   <bold>G</bold>) Survival curve of RVFV-infected mice treated with 200 µg 107-hIgG
   <sub>1</sub>Fc-104. * These chimeric antibodies were produced at medium scale in CHO cells.
  </p>
 </caption>
 <graphic xlink:href="elife-52716-fig6" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
